Vivos Therapeutics Skyrockets 21.7%—Can This Momentum Sustain the Bull Run?

Summary
• Vivos Therapeutics (VVOS) surges 22.4% intraday, trading at $5.27 after opening at $4.15
• Company announces key management hires and Medicare approval for VidaSleep oral appliance
• Intraday range spans $4.12 to $5.69, with 28.2% turnover rate amplifying volatility
• Sector peers like Medtronic (MDT) dip 1.06%, highlighting VVOS’s divergence

Vivos Therapeutics has ignited a dramatic 21.7% rally on Friday, driven by a confluence of strategic hires, regulatory milestones, and a surge in patient acquisition momentum. The stock’s 52-week high of $7.95 remains tantalizingly within reach as the company navigates a pivotal phase in its expansion strategy. With Medicare coverage now securing access for millions of patients, the question looms: can this momentum translate into sustained growth?

Regulatory Wins and Strategic Hires Ignite Investor Optimism
The explosive move in VVOS is directly tied to two catalysts: Medicare approval for its VidaSleep oral appliance and the appointment of Michael Bruhn as Executive Vice President of Business Operations. The Medicare milestone, announced in July, removes a critical barrier for widespread adoption of Vivos’ non-invasive OSA treatment. Meanwhile, Bruhn’s hire—bringing decades of healthcare operational expertise—signals a strategic pivot toward scaling diagnostic and treatment operations. These developments, combined with a recent clinical trial showing efficacy in pediatric patients, have rekindled investor confidence in the company’s ability to capture market share from traditional CPAP devices.

Healthcare Equipment Sector Diverges as VVOS Outperforms
While VVOS surges, the broader Healthcare Equipment & Supplies sector remains mixed. Medtronic (MDT), a sector leader, dipped 1.06% intraday, reflecting broader market skepticism toward medical device valuations. This divergence underscores VVOS’s unique positioning in the high-growth OSA treatment niche. Unlike traditional device makers, Vivos’ focus on non-invasive, scalable solutions aligns with shifting reimbursement policies and patient preferences. However, the sector’s overall weakness—driven by macroeconomic concerns—suggests VVOS’s rally may face headwinds if broader market sentiment deteriorates.

Technical Readings and ETFs Signal High-Risk, High-Reward Setup
• RSI: 13.27 (oversold) – Suggests potential rebound
• MACD: 0.21 vs. Signal Line 0.50 – Negative histogram indicates bearish momentum
• Bollinger Bands: $3.89 (Lower) to $7.19 (Upper) – Price near lower band, hinting at oversold conditions
• 200D MA: $3.52 – Price at 51% above, indicating short-term strength
• Support/Resistance: 30D support at $5.16–5.25; 200D support at $2.66–2.76

VVOS’s technical profile suggests a volatile, overbought short-term trend amid a long-term ranging pattern. The stock has rebounded sharply from the 200-day moving average, with RSI at extreme oversold levels, creating a potential short-term reversal setup. Aggressive traders may consider a $5.50 call option with a July expiration to capitalize on a potential break above the 30D support level. However, the negative MACD histogram and weak sector performance caution against overexposure. For hedging, a $4.50 put option offers downside protection as the stock tests critical support levels. The absence of leveraged ETFs complicates synthetic position construction, but the options market remains the primary vehicle for directional bets.

Backtest Vivos Stock Performance
The backtest of VVOS's performance after a 22% intraday surge shows mixed results. While the stock experienced a positive return, the win rates and returns over different time frames vary. Here's a detailed analysis:1. Event Frequency: The event where VVOS surged by more than 22% intraday occurred 462 times over the backtested period.2. Short-Term Performance: - 3-Day Win Rate: 47.40% of the time, VVOS continued to rise in the three days following the surge, with an average return of 0.81%. - 10-Day Win Rate: The 10-day win rate was slightly lower at 45.67%, with an average return of 2.92%.3. Long-Term Performance: The 30-day win rate was 44.81%, with an average return of 1.57%. The maximum return during this period was 4.74%, which occurred on day 59 after the surge.4. Max Return: The highest return following the surge was 4.74%, indicating that while the stock had the potential for further gains, the likelihood of significant positive movement diminished over time.In conclusion, while a 22% intraday surge in VVOS was followed by positive returns in the short and medium term, the stock's performance gradually tapered off. Investors looking to capitalize on such events should be prepared for varying degrees of success in the days following the initial surge.

Vivos at a Crossroads: Breakout or Bounce?
Vivos Therapeutics stands at a pivotal juncture, with today’s 22.4% rally testing the validity of its long-term growth narrative. The Medicare approval and strategic hires provide a strong foundation, but the stock’s extreme volatility—evidenced by a 28.2% turnover rate—demands caution. Investors must watch the $5.50 level as a key inflection point: a close above this could signal a shift to a bullish bias, while a retest of the $4.12 intraday low would reignite bearish sentiment. Medtronic’s 1.06% decline further highlights the sector’s fragility. For now, VVOS’s momentum suggests a high-risk, high-reward trade, but sustainability will depend on execution against its aggressive expansion goals. Act now: Position for a breakout above $5.50 or secure downside protection below $4.50.